Frederic Vigneault

Unravel Biosciences is a rapid prototyping therapeutics company that uses AI biological network analysis and existing drugs to discover and clinically derisk entirely novel therapeutics and biomarkers for complex diseases. Unravel Biosciences is based in Boston, MA and was founded by Richard Novak, Frederic Vigneault, Michael Levin, and Donald Ingber. The company leverages its proprietary Bionav™ platform to combine target and drug discovery, preclinical screening, and patient stratification. Richard Novak has been the CEO since incorporation.

Unravel Biosciences is a rapid prototyping therapeutics company that uses AI biological network analysis and existing drugs to discover and clinically derisk entirely novel therapeutics and biomarkers for complex diseases. Unravel Biosciences is based in Boston, MA and was founded by Richard Novak, Frederic Vigneault, Michael Levin, and Donald Ingber. The company leverages its proprietary Bionav™ platform to combine target and drug discovery, preclinical screening, and patient stratification. Richard Novak has been the CEO since incorporation.

Unravel Biosciences is a rapid prototyping therapeutics company that uses AI biological network analysis and existing drugs to discover and clinically derisk entirely novel therapeutics and biomarkers for complex diseases. Unravel Biosciences is based in Boston, MA and was founded by Richard Novak, Frederic Vigneault, Michael Levin, and Donald Ingber. The company leverages its proprietary Bionav™ platform to combine target and drug discovery, preclinical screening, and patient stratification. Richard Novak has been the CEO since incorporation.